

<b>INFORMATION DISCLOSURE CITATION</b>  IN AN APPLICATION  FORM PTO 1449 (modified)  (Use several sheets if necessary)		<b>DOCKET NUMBER</b> 50623.169  <b>APPLICANTS:</b> Charles David Claude		<b>APPLICATION NUMBER</b> 09/822,952	
		<b>FILING DATE</b> March 30, 2001		<b>GROUP ART UNIT</b> 1616	
		<b>EXAMINER</b> R. DeWitty			

**RECEIVED**  
 MAY 08 2002  
 TRADEMARK CENTER 1600/2900

OIPE  
 DATE CANCELLED  
 MAY 05 2002  
 PATENT & TRADEMARK OFFICE

OIPE  
 MAY 02 2002  
 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
Rmp	A	2,072,303	3/2/37	Herrmann et al.	128	335.5	
	B	4,882,168	11/21/89	Casey et al.	424	468	
	C	4,977,901	12/18/90	Ofstead	128	772	
	D	5,292,516	3/8/94	Viegas et al.	424	423	
	E	5,298,260	3/29/94	Viegas et al.	424	486	
	F	5,300,295	4/5/94	Viegas et al.	424	427	
	G	5,306,501	4/26/94	Viegas et al.	424	423	
	H	5,328,471	7/12/94	Slepian	604	101	
	I	5,462,990	10/31/95	Hubbell et al.	525	54.1	
	J	5,464,650	11/7/95	Berg et al.	427	2.30	
	K	5,578,073	11/26/96	Haimovich et al.	623	1	
	L	5,628,730	5/13/97	Shapland et al.	604	21	
	M	5,658,995	8/19/97	Kohn et al.	525	432	
	N	5,667,767	9/16/97	Greff et al.	424	9.411	
	O	5,670,558	9/23/97	Onishi et al.	523	112	
	P	5,700,286	12/23/97	Tartaglia et al.	623	1	
	Q	5,716,981	2/10/98	Hunter et al.	514	449	
	R	5,746,998	5/5/98	Torchilin et al.	424	9.4	
	S	5,800,392	9/1/98	Racchini	604	96	
	T	5,824,049	10/20/98	Ragheb et al.	623	1	
	U	5,830,178	11/3/98	Jones et al.	604	49	
	V	5,837,313	11/17/98	Ding et al.	427	2.21	
	W	5,851,508	12/22/98	Greff et al.	424	9.411	
	X	5,865,814	2/2/99	Tuch	604	265	
	Y	5,873,904	2/23/99	Ragheb et al.	623	1	
	Z	5,925,720	7/20/99	Kataoka et al.	525	523	
AA	5,955,509	9/21/99	Webber et al.	514	772.7		
BB	5,971,954	10/26/99	Conway et al.	604	96		
CC	5,980,928	11/9/99	Terry	424	427		
DD	5,980,972	11/9/99	Ding	427	2.24		

**DATE CONSIDERED**  
 6/26/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not information and not considered. Include copy of this with next communication to applicant.

<b>INFORMATION DISCLOSURE CITATION</b>  IN AN APPLICATION  FORM PTO 1449a (modified)  (Use several sheets if necessary)	<b>DOCKET NUMBER</b>  50623.169  <b>APPLICANTS:</b> Charles David Cl...	<b>APPLICATION NUMBER</b>  09/822,952	<b>RECEIVED</b>  MAY 08 2002  TECH CENTER 1600/2900	
	<b>FILING DATE</b>  March 30, 2001	<b>EXAMINER</b>  R. DeWitty		<b>GROUP ART UN</b>  1616

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
Rmd	EE	6,001,382	12/14/99	Levy	424	405	
	FF	6,010,530	1/4/00	Goiceochea	623	1	
	GG	6,015,541	1/18/00	Greff et al.	424	1.25	
	HH	6,060,518	5/9/00	Kabanov et al.	514	781	
	II	6,096,070	8/1/00	Ragheb et al.	623	1	
Rmd	JJ	6,165,212	12/26/00	Dereume et al.	623	1.13	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE OF PUBLICATION	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
Rmd	KK	EP 0 665 023	8/2/95	European			
	LL	EP 0 970 711	1/12/00	European			
	MM	WO 91/12846	9/5/91	PCT			
	NN	WO 97/45105	12/4/97	PCT			
	OO	WO 99/63981	12/16/99	PCT			
	PP	WO 00/12147	3/9/00	PCT			
	QQ	WO 00/64506	11/2/00	PCT			
	RR	WO 01/01890	1/11/01	PCT			
Rmd	SS	WO 01/45763	6/28/01	PCT			

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not information and not considered. Include copy of this with next communication to applicant.

INFORMATION DISCLOSURE CITATION IN AN APPLICATION FORM PTO 14492 (modified) (Use several sheets if necessary)		DOCKET NUMBER 50623.169 APPLICANTS: Charles David Claude FILING DATE March 30, 2001 EXAMINER R. DeWitty	APPLICATION NUMBER 09/822,952 GROUP ART UNIT 1616
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
Rmp	TT	Barath et al., <i>Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury</i> ; JACC Vol. 13, No. 2; February 1989:252A (Abstract).	
	UU	Matsumaru et al., <i>Emboic Materials For Endovascular Treatment of Cerebral Lesions</i> ; J. Biomater. Sci. Polymer Edn, Vol. 8, No. 7 (1997), pp. 555-569.	
	VV	Miyazaki et al., <i>Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice</i> , Chem. Pharm. Bull. 33(6) (1985), pp. 2490-2498.	
	WW	Miyazawa et al., <i>Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat</i> ; J. Cardiovasc. Pharmacol. (1997), pp. 157-162.	
	XX	Ohsawa et al.; <i>Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty</i> ; American Heart Journal (Dec. 1998); pp. 1081-1087.	
	YY	Pechar et al., <i>Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin</i> , Bioconjugate Chemistry, March/April 2000, pp. 131-139; Vol. 11, No. 2, Published by American Chemical Society.	
Rmd	ZZ	Shigeno, <i>Prevention of Cerebrovascular Spasm by Bosentan, Novel Endothelin Receptor</i> ; Chemical Abstract 125:212307 (1996).	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not information and not considered. Include copy of this with next communication to applicant.		DATE CONSIDERED 6/26/02	